Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Bioregenx (BRGX) EPS (Weighted Average and Diluted) (2022 - 2025)

Bioregenx has reported EPS (Weighted Average and Diluted) over the past 4 years, most recently at -$0.0 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 94.7% year-over-year to -$0.0; the TTM value through Dec 2025 reached -$0.0, up 91.96%, while the annual FY2025 figure was -$0.0, 94.64% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.0 at Bioregenx, down from -$0.0 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at -$0.0 in Q2 2023 and troughed at -$0.02 in Q4 2024.
  • A 4-year average of -$0.0 and a median of -$0.0 in 2025 define the central range for EPS (Weighted Average and Diluted).
  • Biggest five-year swings in EPS (Weighted Average and Diluted): soared 95.61% in 2023 and later plummeted 21246.47% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.0 in 2022, then crashed by 5384.25% to -$0.0 in 2023, then crashed by 1677.25% to -$0.02 in 2024, then soared by 94.7% to -$0.0 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for BRGX at -$0.0 in Q4 2025, -$0.0 in Q3 2025, and -$0.0 in Q2 2025.